Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Dow Jones Top Company Headlines at 11 AM ET: Meta Directors, Shareholders Settle Privacy Suit Before Board Members Testify at Trial | FDA ... Meta Directors, Shareholders Settle Privacy Suit Before ...

Accenture downgraded to neutral amid soft bookings, weak guidance, and demand uncertainty. See here to know more on ACN stock ...

Futures on Wall Street reversed early losses and are trading with gains, particularly those on the Nasdaq. Futures on the Dow ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

The pharmaceutical company posted higher earnings and sales for the second quarter, and said longtime financial chief Harry ...

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.